paclitaxel has been researched along with Sarcopenia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 1 |
| Gu, M; Guo, J; Hou, J; Jiang, C; Jiang, Y; Jin, G; Li, H; Li, Q; Li, X; Li, Z; Liu, G; Liu, T; Qian, Y; Ren, B; Shen, J; Shi, Y; Xu, T; Zhang, Z; Zhao, J; Zhao, L; Zhou, T | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Suzumori, C; Takeda, T; Yamada, Y | 1 |
1 review(s) available for paclitaxel and Sarcopenia
| Article | Year |
|---|---|
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
1 trial(s) available for paclitaxel and Sarcopenia
| Article | Year |
|---|---|
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
5 other study(ies) available for paclitaxel and Sarcopenia
| Article | Year |
|---|---|
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Hypoalbuminemia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2022 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2021 |